BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37076396)

  • 1. Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System.
    Yegya-Raman N; Friedes C; Sun L; Iocolano M; Kim KN; Doucette A; Cohen RB; Robinson KW; Levin WP; Cengel KA; Lally B; Agarwal M; D'Avella CA; Marmarelis ME; Kosteva JA; Singh AP; Ciunci CA; Aggarwal C; Berman AT; Langer CJ; Feigenberg SJ
    Clin Lung Cancer; 2023 Jul; 24(5):474-482. PubMed ID: 37076396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
    Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
    Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).
    Choi J; Lee JE; Choi CM; Oh IJ; Lee KY; Jang TW; Lee SH; Kim EY; Park DW; Park SH; Lee SY
    Thorac Cancer; 2022 Dec; 13(23):3431-3435. PubMed ID: 36259253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review.
    Zhang T; Xu K; Bi N; Zhang L; Jiang W; Liang J; Deng L; Wang X; Wang J; Wang J; Wang L
    Thorac Cancer; 2020 Oct; 11(10):2916-2923. PubMed ID: 32833338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
    Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
    J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study.
    Wang CC; Chiu LC; Ju JS; Lin YC; Fang YF; Yang CT; Hsu PC
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
    Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
    Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study.
    Jang JY; Kim SS; Song SY; Kim YJ; Kim SW; Choi EK
    Radiat Oncol; 2021 Dec; 16(1):231. PubMed ID: 34863244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
    Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
    Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a
    An J; Yan M; Yu N; Chennamadhavuni A; Furqan M; Mott SL; Loeffler BT; Kruser T; Sita TL; Feldman L; Nguyen R; Pasquinelli M; Hanna NH; Abu Hejleh T
    Transl Lung Cancer Res; 2021 Aug; 10(8):3608-3615. PubMed ID: 34584860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
    Nakamichi S; Kubota K; Misumi T; Kondo T; Murakami S; Shiraishi Y; Imai H; Harada D; Isobe K; Itani H; Takata S; Wakui H; Misumi Y; Ikeda S; Asao T; Furuya N; Hosokawa S; Kobayashi Y; Takiguchi Y; Okamoto H
    Clin Cancer Res; 2024 Mar; 30(6):1104-1110. PubMed ID: 38165684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
    Bi N; Liang J; Zhou Z; Chen D; Fu Z; Yang X; Feng Q; Hui Z; Xiao Z; Lv J; Wang X; Zhang T; Wang X; Deng L; Wang W; Wang J; Liu L; Hu C; Wang L
    JAMA Netw Open; 2019 Dec; 2(12):e1918070. PubMed ID: 31851351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab.
    Thor M; Shepherd AF; Preeshagul I; Offin M; Gelblum DY; Wu AJ; Apte A; Simone CB; Hellmann MD; Rimner A; Chaft JE; Gomez DR; Deasy JO; Shaverdian N
    Radiother Oncol; 2022 Feb; 167():158-164. PubMed ID: 34942280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation.
    Yegya-Raman N; Friedes C; Lee SH; Iocolano M; Duan L; Wang X; Li B; Aggarwal C; Cohen RB; Su W; Doucette A; Levin WP; Cengel KA; DiBardino D; Teo BK; O'Reilly SE; Sun L; Bradley JD; Xiao Y; Langer CJ; Feigenberg SJ
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1445-1454. PubMed ID: 37619788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
    De Ruysscher D; Ramalingam S; Urbanic J; Gerber DE; Tan DSW; Cai J; Li A; Peters S
    Clin Lung Cancer; 2022 May; 23(3):e264-e268. PubMed ID: 34489161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
    Aredo JV; Mambetsariev I; Hellyer JA; Amini A; Neal JW; Padda SK; McCoach CE; Riess JW; Cabebe EC; Naidoo J; Abuali T; Salgia R; Loo BW; Diehn M; Han SS; Wakelee HA
    J Thorac Oncol; 2021 Jun; 16(6):1030-1041. PubMed ID: 33588109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.
    Guo MZ; Murray JC; Ghanem P; Voong KR; Hales RK; Ettinger D; Lam VK; Hann CL; Forde PM; Brahmer JR; Levy BP; Feliciano JL; Marrone KA
    Clin Lung Cancer; 2022 Nov; 23(7):620-629. PubMed ID: 36045016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations.
    Cortiula F; De Ruysscher D; Steens M; Wijsman R; van der Wekken A; Alberti M; Hendriks LEL
    Eur J Cancer; 2023 May; 184():172-178. PubMed ID: 36931075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer.
    Kashihara T; Nakayama Y; Okuma K; Takahashi A; Kaneda T; Katagiri M; Nakayama H; Kubo Y; Ito K; Nakamura S; Takahashi K; Inaba K; Murakami N; Saito T; Okamoto H; Itami J; Kusumoto M; Ohe Y; Igaki H
    Radiother Oncol; 2023 Mar; 180():109454. PubMed ID: 36640944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.